FM
SAGE

Forward Management’s Sage Therapeutics SAGE Stock Holding History

Forward Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-32,475
Closed -$2.47M – 297
2015
Q2 		$2.47M Buy
+32,475
New +$2.09M 0.15% 94

Other funds holding SAGE

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Forward Management's SAGE Position: Q3 2015 in Review

Forward Management sold out of Sage Therapeutics (SAGE) in Q3 2015, closing a stake of 32,475 shares — an estimated $2.47M sold.

Forward Management first reported a position in SAGE in Q2 2015 and held it in 1 quarter. The position peaked at $2.47M in Q2 2015. 134 funds tracked by Wall St. Rank hold SAGE as of Q3 2015.

  • Forward Management reported no remaining Sage Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Forward Management sold 32,475 Sage Therapeutics shares in Q3 2015, an estimated $2.47M.
  • Forward Management first reported a position in Sage Therapeutics in Q2 2015 and held it in 1 quarter.
  • Forward Management's Sage Therapeutics position peaked at $2.47M in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2015.

Based on Forward Management's 13F filing for Q3 2015, filed 9 Nov 2015.